Case for adoptive immunotherapy in cancer.
Patients with normal immune systems may be unable to mount effective defences against solid tumours because of (1) the generation of suppressor T cells in the low zone tolerance response elicited by the low concentrations of antigen furnished by slow growing solid tumours; (2) the ineffectiveness of the cytolytic T-cell response when the tumour cell membrane lacks the major histocompatibility gene products required for linkage to tumour antigens; and (3) the hindrance of antibody-dependent cellular cytotoxicity by antitumour antibodies when the precise requirements for the reaction cannot be fulfilled in the sites occupied by solid tumours. Recent immunological advances suggest that it should be possible to isolate antigens from cancer cells, produce antibodies against these antigens, bind the antibodies to the patient's macrophages and K lymphocytes, and reinject the bound cells into the patients to stimulate lymphokine synthesis and antibody-dependent cellular cytoxicity.
D000912:Antibodies, Neoplasm / Q000276:immunology; D000920:Antibody-Dependent Cell Cytotoxicity; D000951:Antigens, Neoplasm / Q000276:immunology; D001943:Breast Neoplasms / Q000276:immunology; D006801:Humans; D007114:Immunization; D007167:Immunotherapy; D007694:Killer Cells, Natural / Q000276:immunology; D008285:Major Histocompatibility Complex; D008954:Models, Biological; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011961:Receptors, Fc / Q000276:immunology
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D011961:Receptors, Fc